Novartis: Arthritis, Psoriatic trials

The registry lists 31 Arthritis, Psoriatic studies with Novartis as lead sponsor. 3 are open to participants now and 19 have results posted.

Phase 1 1Phase 2 5Phase 3 14Phase 4 1No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)Not yet recruitingNCT07923773Phase 2
• A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisRecruitingNCT07801495Phase 2
• Modifying PEST for Psoriatic Arthritis ScreeningRecruitingNCT06382051Not applicable
• A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)CompletedNCT05758402Not applicableResults posted
• Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.CompletedNCT04711902Phase 3Results posted
• Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor TreatmentCompletedNCT04632927Phase 3Results posted
• Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic ArthritisCompletedNCT04209205Phase 3Results posted
• 99mTc-rhAnnexin V-128 in Diagnosis of SpondyloarthritisTerminatedNCT03232580Phase 2Results posted
• Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to PlaceboCompletedNCT02798211Phase 4Results posted
• Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon SiteCompletedNCT02771210Phase 3Results posted
• Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic ArthritisCompletedNCT02745080Phase 3Results posted
• Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton InvolvementCompletedNCT02721966Phase 3Results posted
• Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT02662985Phase 3Results posted
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic ArthritisCompletedNCT02404350Phase 3Results posted
• 16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic ArthritisCompletedNCT02294227Phase 3Results posted
• 24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic ArthritisCompletedNCT01989468Phase 3Results posted
• Extension Study up to 3 Years for Secukinumab in Psoriatic ArthritisCompletedNCT01892436Phase 3Results posted
• Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic ArthritisCompletedNCT01752634Phase 3Results posted
• Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)CompletedNCT01392326Phase 3Results posted
• Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 YearCompletedNCT01365455Phase 3Results posted
• Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic ArthritisCompletedNCT01169844Phase 2Results posted
• Efficacy of AIN457 in Adults (18-65 Years) With Psoriatic ArthritisCompletedNCT00809614Phase 2Results posted
• A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in BrazilTerminatedNCT06715254
• Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab EnvironmentCompletedNCT06666114
• Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims DatabaseCompletedNCT06600009
• Incidence of Psoriatic Arthritis Among Psoriasis Patients Newly Initiated With Secukinumab in a US Claims Database and a UK RegistryCompletedNCT06172426
• Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): Spanish Multicenter, Retrospective, Real World Evidence StudyCompletedNCT05677542
• Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPPCompletedNCT05215561
• 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial SpondyloarthritisCompletedNCT05155098
• A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic ArthritisCompletedNCT04614831
• To Demonstrate the Relative Bioavailability, Parallel Study Of Leflunomide 20 mg Tablets Under Fasting ConditionsCompletedNCT00946686Phase 1